OCGN
NASDAQ · Biotechnology
Ocugen Inc
$1.06
+0.03 (+2.91%)
Open$1.03
Previous Close$1.03
Day High$1.09
Day Low$1.00
52W High$2.73
52W Low$0.97
Volume—
Avg Volume10.91M
Market Cap349.28M
P/E Ratio—
EPS$-0.20
SectorBiotechnology
Analyst Ratings
Strong Buy
12 analysts
Price Target
+2,727.4% upside
Current
$1.06
$1.06
Target
$29.97
$29.97
$22.68
$29.97 avg
$39.58
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 4.84M | 214.85M | 205.76M |
| Net Income | -74,469,925 | -16,849,465 | -19,542,916 |
| Profit Margin | -1,537.4% | -7.8% | -9.5% |
| EBITDA | -66,429,809 | -26,350,714 | -23,624,019 |
| Free Cash Flow | — | -15,177,197 | -13,829,123 |
| Rev Growth | — | +3.8% | +8.3% |
| Debt/Equity | 0.97 | 0.42 | 0.45 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $265.08 | -0.05% | 74.0 | 466.74B |
| AMGN | Amgen Inc | $406.09 | -1.01% | 23.7 | 207.25B |
| GILD | Gilead Sciences Inc | $151.37 | -0.85% | — | 187.10B |
| VRTX | Vertex Pharmaceuticals Inc | $516.34 | +0.26% | 29.7 | 130.64B |
| REGN | Regeneron Pharmaceuticals | $801.82 | -0.26% | 18.6 | 80.58B |
| ALNY | Alnylam Pharmaceuticals Inc | $246.51 | -2.04% | 40.0 | 32.33B |